Prednisolone

Generic Name: Prednisolone

Brand Names: Millipred Dp 6 Day

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₈O_₅

CAS Number: 50-24-8

Unique Ingredient Identifier: 9PHQ9Y1OLM

Background: Prednisolone is a glucocorticoid similar to cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.

Prednisolone was granted FDA approval on 21 June 1955.

Indication: Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Contact Dermatitis, Allergic Skin Reaction, Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonia, Aspiration Pneumonitis, Atopic Dermatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Burns, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Corneal injuries, Corneal ulceration, Crohn's Disease (CD), Cyclitis, Dermatomyositis (DM), Dermatosis of the Ear Canal, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Exacerbation of COPD, Exacerbation of asthma, Eye inflammation caused by Cataract Surgery, Eye inflammation caused by Infection, Fissure;Anal, Herpes Zoster Keratitis, Hot Water Burns (Scalds), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Inflamed External Hemorrhoid, Inflamed Hemorrhoids, Internal, Inflammatory Reaction caused by susceptible Bacterial Infections, Iridocyclitis, Iritis, Itching caused by susceptible Bacterial Infections, Keratitis, Loeffler's syndrome, Lymphoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Otic Eczema, Pemphigus, Perennial Allergic Rhinitis (PAR), Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Posterior Uveitis, Posttraumatic Osteoarthritis, Proctitis, Proteinuria, Pruritus, Pruritus Ani, Psoriatic Arthritis, Pulmonary Tuberculosis (TB), Pure Red Cell Aplasia, Rash, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Seasonal Allergic Rhinitis, Secondary Adrenal Insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Asthma, Sjogren's Syndrome (SS), Stevens-Johnson Syndrome, Superficial punctate keratitis, Synovitis, Systemic Lupus Erythematosus, Transplanted Organ Rejection, Trichinosis, Tuberculosis (TB), Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Rheumatic heart disease, unspecified, Acute Tenosynovitis, Anal eczema, Bacterial skin infections, Exfoliative erythroderma, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Primary adrenocoritical insufficiency, Severe Psoriasis, Severe Seborrhoeic dermatitis, Severe alcoholic liver disease, Steroid-responsive inflammation of the eye, Subacute Bursitis, Susceptible Bacterial Infections, Symptomatic Sarcoidosis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: -

Clinical Trials

Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)

Phase 1

Terminated

Conditions: Follicular Lymphoma

Interventions: Drug: MK-8808
Drug: cyclophosphamide
Drug: vincristine
Drug: prednisolone

First Posted Date: 2011-06-10

Last Posted Date: 2019-03-15

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 7

Registration Number: NCT01370694

A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Z102
Other: placebo
Drug: Prednisolone
Drug: dipyridamole
Drug: Prednisone

First Posted Date: 2011-06-09

Last Posted Date: 2014-05-15

Lead Sponsor: Zalicus

Target Recruit Count: 294

Registration Number: NCT01369745

Locations: 🇺🇸
Zalicus Investigational Site, Toledo, Ohio, United States

Oral Prednisolone in Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: COPD Exacerbation

Interventions: Drug: usual care
Drug: Prednisolone

First Posted Date: 2011-05-13

Last Posted Date: 2017-08-01

Lead Sponsor: Fekri Abroug

Target Recruit Count: 317

Registration Number: NCT01353235

Locations: 🇹🇳
CHU F.Bourguiba, Monastir, Tunisia

Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Cabazitaxel (XRP6258)
Drug: prednisolone

First Posted Date: 2011-03-29

Last Posted Date: 2015-01-07

Lead Sponsor: Sanofi

Target Recruit Count: 48

Registration Number: NCT01324583

Locations: 🇯🇵
Investigational Site Number 392008, Maebashi-Shi, Japan
🇯🇵
Investigational Site Number 392015, Nagoya-Shi, Japan
🇯🇵
Investigational Site Number 392003, Sunto-Gun, Japan

and more 18 locations

A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients

Phase 3

Conditions: Follicular Lymphoma

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Vincristine
Drug: Prednisolone

First Posted Date: 2011-02-25

Last Posted Date: 2011-05-06

Lead Sponsor: University of Liverpool

Target Recruit Count: 680

Registration Number: NCT01303887

Locations: 🇬🇧
Queen's Hospital, Burton, Burton-upon-Trent, United Kingdom
🇬🇧
Princess Royal Hospital, Bromley, Hayes, United Kingdom
🇬🇧
Trafford General Hospital, Davyhulme, United Kingdom

and more 70 locations

Progression of HIV-Disease Under Low Dose Corticosteroids

Phase 2

Completed

Conditions: HIV Disease Progression

Interventions: Drug: Prednisolone

First Posted Date: 2011-02-21

Last Posted Date: 2013-03-22

Lead Sponsor: Medical Mission Institute, Germany

Target Recruit Count: 326

Registration Number: NCT01299948

Locations: 🇹🇿
Bugando Medical Center, Mwanza, Tanzania

Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions

Not Applicable

Completed

Conditions: Drug Hypersensitivity

Interventions: Drug: anti- TNF-a
Drug: Prednisolone

First Posted Date: 2011-01-13

Last Posted Date: 2017-12-19

Lead Sponsor: Chang Gung Memorial Hospital

Target Recruit Count: 135

Registration Number: NCT01276314

Locations: 🇨🇳
Department of Dermatology, Chang Gung Memorial hospital, Taipei, Taiwan

The Effect of Moderate-Dose Steroid Therapy in Sepsis

Phase 4

Completed

Conditions: Sepsis

Interventions: Drug: Prednisolone

First Posted Date: 2011-01-12

Last Posted Date: 2011-01-12

Lead Sponsor: TC Erciyes University

Target Recruit Count: 55

Registration Number: NCT01275638

Treatment of Preschool Children With Upper Respiratory Tract Illnesses Using Azythromycin and Lower Respiratory Tract Symptoms Using Oral Corticosteroids.

Phase 3

Completed

Conditions: Asthma
Wheezing

Interventions: Drug: Prednisolone
Drug: Azithromycin
Drug: Placebo Prednisolone
Other: Placebo Azithromycin

First Posted Date: 2011-01-10

Last Posted Date: 2016-12-28

Lead Sponsor: Milton S. Hershey Medical Center

Target Recruit Count: 607

Registration Number: NCT01272635

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
University of Arizona College of Medicine, Tucson, Arizona, United States

and more 13 locations

Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)

Phase 4

Terminated

Conditions: Leukoencephalopathy, Progressive Multifocal
Immune Reconstitution Inflammatory Syndrome

Interventions: Drug: Methylprednisolone
Drug: Prednisolone

First Posted Date: 2010-09-29

Last Posted Date: 2014-09-05

Lead Sponsor: Biogen

Target Recruit Count: 3

Registration Number: NCT01211665

Locations: 🇩🇪
Research Site, Wurzburg, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy